Cogent Biosciences (COGT) Capital Expenditures (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Capital Expenditures of $449000.0 for Q1 2026, down 17.92% year-over-year from $547000.0 in Q1 2025, and down 44.64% quarter-over-quarter from $811000.0 in Q4 2025.
Cogent Biosciences (COGT) Capital Expenditures (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Capital Expenditures for 9 consecutive years, with $449000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 17.92% year-over-year to $449000.0; the TTM figure through Mar 2026 stood at $1.5 million (up 38.67% YoY), while the FY2025 annual figure was $1.6 million, up 171.2% from the prior year.
- Capital Expenditures retreated to $449000.0 in Q1 2026 per COGT's latest filing, from $811000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.3 million in Q3 2022 and bottomed at $65000.0 in Q3 2025.
- Historically, Capital Expenditures has averaged $719705.9 across 5 years, with a median of $441000.0 in 2022.
- Annual changes were most pronounced in 2023 — Capital Expenditures slumped 96.35% — and 2025, when it surged 981.33%.
- Cogent Biosciences' Capital Expenditures stood at $2.0 million in 2022, then plunged by 83.99% to $315000.0 in 2023, then tumbled by 76.19% to $75000.0 in 2024, then soared by 981.33% to $811000.0 in 2025, then slumped by 44.64% to $449000.0 in 2026.
- Business Quant data shows COGT's Capital Expenditures at $449000.0 in Q1 2026, $811000.0 in Q4 2025, and $65000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 370,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 370,000.00 |
| Jun 30, 2026 | 370,000.00 |
| Mar 31, 2026 | 449,000.00 |
| Mar 31, 2026 | 449,000.00 |
| Dec 31, 2025 | 811,000.00 |
| Dec 31, 2025 | 811,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Sep 30, 2025 | 65,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Jun 30, 2025 | 131,000.00 |
| Mar 31, 2025 | 547,000.00 |
| Mar 31, 2025 | 547,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 280,000.00 |
| Sep 30, 2024 | 280,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Jun 30, 2024 | 148,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |